FRED HUTCHINSON CANCER RESEARCH CENTER

🇺🇸United States

Active:5

Completed:2

3 Phases

Phase 1:4

Phase 4:1

Not Applicable:3

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials

Phase 1

4 (50.0%)

Not Applicable

3 (37.5%)

Phase 4

1 (12.5%)

No trials found

4 years ago

Research indicates pembrolizumab, an immunotherapy drug, can reactivate latent HIV in immune cells, making the virus visible to the immune system.